CD7 is a transmembrane glycoprotein expressed on T cells and natural killer (NK) cells that serves as a costimulatory receptor for immune activation 1. Upon binding to its ligand K12/SECTM1, CD7 promotes T-cell activation and cytokine production, including IL-2 23. On resting NK cells, CD7 activation induces interferon-gamma production 1. CD7 has emerged as a validated immunotherapeutic target for T-cell malignancies, particularly acute T-cell leukemia (T-ALL) and peripheral T-cell lymphomas 4. Its restricted expression on T and NK cells reduces off-target toxicity risk compared to other T-lineage antigens 4. Multiple clinical approaches have successfully leveraged CD7 for CAR-T cell therapy: genetically edited CD7-negative CAR-T cells 4, naturally selected CD7-masked CAR-T cells 5, nanobody-based fratricide-resistant variants 6, pharmacologically inhibited unedited CAR-T cells 7, allogeneic CAR-T cells 8, and pluripotent stem cell-derived CAR-NK cells 9. Phase I clinical trials demonstrate complete remission rates of 63.6-90% in relapsed/refractory T-ALL patients with manageable toxicity profiles 56108. Notably, CD7+ monocytes also regulate metabolic homeostasis and weight regain through adipose tissue remodeling 11.